REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights
REGENXBIO (Nasdaq: RGNX) will host a conference call on Thursday, November 6, 2025 at 8:00 a.m. ET to discuss third quarter financial results for the period ended September 30, 2025 and operational highlights.
Listeners can register for a live webcast via the company website, analysts may use a separate link to join the Q&A, and a replay will be available on the investor website approximately two hours after the call concludes. Participants are advised to join 15 minutes early.
REGENXBIO (Nasdaq: RGNX) terrà una conference call giovedì 6 novembre 2025 alle 8:00 ET per discutere i risultati finanziari del terzo trimestre per il periodo terminato il 30 settembre 2025 e i punti salienti operativi.
Gli ascoltatori possono registrarsi per una trasmissione webcast in diretta tramite il sito aziendale, gli analisti possono utilizzare un link separato per partecipare al Q&A, e una riproduzione sarà disponibile sul sito degli investitori circa due ore dopo la chiusura della chiamata. Si consiglia ai partecipanti di collegarsi 15 minuti prima.
REGENXBIO (Nasdaq: RGNX) organizará una conferencia telefónica el jueves 6 de noviembre de 2025 a las 8:00 a. m., hora del Este, para discutir los resultados financieros del tercer trimestre correspondientes al periodo terminado el 30 de septiembre de 2025 y los aspectos operativos destacados.
Los oyentes pueden registrarse para una transmisión en directo a través del sitio web de la empresa; los analistas pueden usar un enlace separado para unirse al Q&A, y se dispondrá de una repetición en el sitio de inversores aproximadamente dos horas después de que concluya la llamada. Se recomienda a los participantes unirse 15 minutos antes.
REGENXBIO(나스닥: RGNX)는 2025년 11월 6일 목요일 동부 표준시 8:00에 컨퍼런스 콜을 진행하여 2025년 9월 30일 종료 기간의 제3분기 재무실적 및 운영 하이라이트를 논의합니다.
청취자는 회사 웹사이트를 통해 라이브 웹캐스트에 등록할 수 있으며, 애널리스트는 Q&A에 참여하기 위한 별도 링크를 사용할 수 있고 콜 종료 약 두 시간 후 투자자 웹사이트에서 재방송을 이용할 수 있습니다. 참가자는 15분 일찍 접속하는 것이 좋습니다.
REGENXBIO (Nasdaq : RGNX) organisera une conférence téléphonique jeudi 6 novembre 2025 à 8h00, heure de l'Est, pour discuter des résultats financiers du troisième trimestre pour la période se terminant le 30 septembre 2025 et des points forts opérationnels.
Les auditeurs peuvent s'inscrire pour une diffusion en direct via le site Web de l'entreprise, les analystes peuvent utiliser un lien distinct pour rejoindre la séance de questions-réponses, et une retransmission sera disponible sur le site des investisseurs environ deux heures après la fin de l'appel. Il est conseillé aux participants de se connecter 15 minutes plus tôt.
REGENXBIO (Nasdaq: RGNX) wird am Donnerstag, dem 6. November 2025 um 8:00 Uhr ET eine Konferenzschaltung abhalten, um die Finanzergebnisse des dritten Quartals für den Zeitraum bis zum 30. September 2025 sowie operative Highlights zu besprechen.
Zuhörer können sich für eine Live-Webcast über die Website des Unternehmens registrieren, Analysten können einen separaten Link nutzen, um am Q&A teilzunehmen, und eine Wiederholung wird ca. zwei Stunden nach Abschluss des Anrufs auf der Investoren-Website verfügbar sein. Teilnehmer sollten sich 15 Minuten früher einwählen.
ستعقد REGENXBIO (ناسداك: RGNX) مكالمة جماعية يوم الخميس 6 نوفمبر 2025 في الساعة 8:00 صباحاً بتوقيت شرق الولايات المتحدة لمناقشة نتائج الربع الثالث للفترة المنتهية في 30 سبتمبر 2025 وأبرز النقاط التشغيلية.
يمكن للمستمعين التسجيل لبث حي عبر موقع الشركة على الويب، ويمكن للمحللين استخدام رابط منفصل للانضمام إلى الأسئلة والأجوبة، وسيكون هناك إعادة بث متاحة على موقع المستثمرين تقريباً بعد نحو ساعتين من انتهاء المكالمة. يُنصح المشاركون بالانضمام قبل 15 دقيقة.
REGENXBIO（纳斯达克股票代码：RGNX） 将于美东时间 2025 年 11 月 6 日星期四 8:00 举行电话会议，讨论截止至 2025 年 9 月 30 日的第三季度财务业绩及运营要点。
听众可以通过公司网站注册收看现场网络广播，分析师可以使用单独的链接加入问答环节，电话结束后大约两小时，投资者网站将提供回放。参与者建议提前 15 分钟 连接。
- None.
- None.
Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.
ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-november-6-to-discuss-third-quarter-2025-financial-results-and-operational-highlights-302598006.html
SOURCE REGENXBIO Inc.
FAQ
When will REGENXBIO (RGNX) discuss Q3 2025 results?
What period do the Q3 2025 results cover for REGENXBIO (RGNX)?
How can I listen to the REGENXBIO (RGNX) November 6, 2025 conference call webcast?
Can analysts ask questions during the REGENXBIO (RGNX) Q3 2025 call?
Will a replay of the REGENXBIO (RGNX) November 6, 2025 call be available?
Is there a recommended arrival time for the REGENXBIO (RGNX) webcast?
